Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06209580
Other study ID # AMT-253-02
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date January 31, 2024
Est. completion date December 31, 2025

Study information

Verified date December 2023
Source Multitude Therapeutics Inc.
Contact Minqi Guan
Phone 86-15895820062
Email minqi.guan@multitudetherapeutics.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a non-randomized, open-label, multicenter Phase I/II study of AMT-253 in patients with Unresectable or Metastatic Malignant Melanoma and other Advanced Solid Tumors. This study include phase I dose escalation and phase II dose expansion.


Recruitment information / eligibility

Status Recruiting
Enrollment 96
Est. completion date December 31, 2025
Est. primary completion date April 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - 1. Patients must be willing and able to understand and sign the ICF, and to adhere to the study visit schedule and other protocol requirements. - 2. Patients with histologically confirmed melanoma or other advanced solid tumor. - 3. Patients who have undergone at least one systemic therapy and have radiologically or clinically determined progressive disease (PD) during or after most recent line of therapy, and for whom no further standard therapy is available, or who are intolerable to standard therapy. - 4. Patients must have at least one measurable lesion as per RECIST version 1.1. - 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. - 6. Life expectancy = 3 months. - 7. Patients must have adequate organ function - 8. Women of child bearing potential (WCBP), defined as a sexually mature woman who has not undergone surgical sterilization or who has not been naturally postmenopausal for at least 12 consecutive months must agree to use two effective contraceptive methods while on study treatment and for at least twelve weeks after the last dose of the IMP. - 9. WCBP must have a negative serum pregnancy test within 7 days prior to first dose of the IMP. - 10. Male patients must agree to use a latex condom, even if they had a successful vasectomy, while on study treatment and for at least twelve weeks after the last dose of the IMP. - 11. Male patients must agree not to donate sperm, and female patients must agree not to donate eggs, while on study treatment and for at least 12 weeks after the last dose of the IMP. - 12. Availability of tumor tissue sample at screening. Exclusion Criteria: - 1. Prior treatment with any agent that has the same target. - 2. Central nervous system (CNS) metastasis. - 3. Active or chronic skin disorder requiring systemic therapy. - 4. History of Steven's Johnson's syndrome or toxic epidermal necrolysis syndrome. - 5. Persistent toxicities from previous systemic anti-neoplastic treatments of Grade >1. - 6. Systemic anti-neoplastic therapy within five half-lives or 21 days, whichever is shorter, prior to first dose of the IMP. - 7. Major surgery within 28 days prior to first dose of the IMP, or no recovery from side effects of such intervention. - 8. Significant cardiac disease, such as recent myocardial infarction or acute coronary syndromes, congestive heart failure, uncontrolled hypertension, uncontrolled cardiac arrhythmias. - 9. History of thromboembolic or cerebrovascular events, including transient ischemic attacks, cerebrovascular accidents, deep vein thrombosis, or pulmonary emboli within six months prior to first dose of the IMP. - 10. Acute and/or clinically significant bacterial, fungal or viral infection including hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV). - 11. Administration of a live vaccine within 28 days prior to the administration of the first dose of the IMP.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
AMT-253 for injection
Administered intravenously

Locations

Country Name City State
China Beijing Cancer Hospital Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Multitude Therapeutics Inc.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary DLTs Incidence of dose limiting toxicities 21 days after first dose
Primary AEs Type, incidence and severity of Adverse Events Up to 24 months
Primary SAEs Type, incidence and severity Serious Adverse Events (SAEs) Up to 24 months
Primary ORR Overall response rate assessed by the investigator according to RECIST version 1.1 Up to 24 months
Secondary Cmax aximum concentration (Cmax) Up to 24 months
Secondary Tmax time to peak drug concentration Up to 24 months
Secondary AUC Area Under the Curve Up to 24 months
Secondary t1/2 terminal half-life of the ADC, total antibody and free payload Up to 24 months
Secondary ADAs Specification and quantification of anti-drug antibodies Up to 24 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04972981 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors Phase 1
Completed NCT05086822 - A Study of Irinotecan Hydrochloride Liposome in Advanced Solid Tumors Phase 1
Completed NCT03260322 - A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors Phase 1
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Recruiting NCT06040541 - Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumors Phase 1
Recruiting NCT05862831 - Clinical Study of PM1003 in Phase I/IIa Treatment of Advanced Malignant Solid Tumors Phase 1/Phase 2
Recruiting NCT03641794 - Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers Phase 1
Terminated NCT03665129 - IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors Phase 1
Not yet recruiting NCT06413680 - A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies Phase 1/Phase 2
Recruiting NCT05914116 - A Study of DB-1311 in Advanced/Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT01693562 - A Phase 1/2 Study to Evaluate MEDI4736 Phase 1/Phase 2
Recruiting NCT04387916 - A Study of KC1036 in Patients With Advanced Solid Tumors Phase 1
Completed NCT04095273 - Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug Phase 1
Not yet recruiting NCT03692520 - Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SCT200 in Patients With Advanced Solid Tumors Phase 1
Completed NCT02997176 - An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800) Phase 1
Recruiting NCT04446260 - A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors Phase 1
Recruiting NCT06239155 - A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Terminated NCT02253992 - An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma Phase 1/Phase 2
Recruiting NCT06076291 - An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors Phase 1
Completed NCT03545971 - A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors. Phase 1